髓新获益
当然之选
由国际骨髓瘤学会(IMS)主办的第23届IMS年会(23rd IMS Annual Meeting & Exposition)将于2026年9月23–26日在英国格拉斯哥ScottishEventsCampus(SEC)举行,注射用埃普奈明4项基础/临床研究成果确认收录大会壁报展示环节,内容涵盖埃普奈明方案疗效生物标志物的探索分析、埃普奈明联合蛋白酶体抑制剂、免疫调节剂、细胞毒类药物及BCL-2抑制剂联合治疗方案的有效性及安全性评价,涉及免疫治疗后复发、多药暴露等面临较大治疗挑战的复发难治多发性骨髓瘤人群。
注射用埃普奈明为人肿瘤坏死因子相关凋亡诱导配体(TRAIL)的环化变构体,是全球首个上市的DR4/DR5激动剂,通过结合肿瘤细胞膜上的死亡受体4(DR4)和/或死亡受体5(DR5)激活外源性细胞凋亡通路,触发细胞内含半胱氨酸的天冬氨酸蛋白水解酶(Caspase)的级联反应,诱导不依赖P53的细胞凋亡。此外,多项研究表明,DR4/DR5激动剂还具有免疫调节作用,对肿瘤微环境中的调节性T细胞、肿瘤相关巨噬细胞、骨髓源性抑制细胞等具有抑制作用,有助于改善肿瘤免疫微环境。
作为全球骨髓瘤领域极具权威性的年度学术盛会,IMS年会始终聚焦多发性骨髓瘤及浆细胞疾病的基础研究、转化医学与临床实践。会议汇聚全球顶尖专家,覆盖新诊断/复发难治MM、CAR-T疗法、双特异性抗体疗法、MRD检测技术与评估标准等前沿议题,诸多关键临床试验选择在此首发,是骨髓瘤诊疗前沿动态的核心风向标。
近年来,涵盖注射用埃普奈明的基础研究、真实世界病例分析及研究者发起临床研究早期、中期数据已相继亮相在IMS年会等全球顶级学术会议,相关内容从研究思路设计到靶点作用机制的深度解析,充分体现了国际血液学界对DR4/DR5激动剂用于血液肿瘤治疗的认可,也体现出业界对其作用机制的认知在持续深化。武汉海特生物制药股份有限公司也将加速推进现有研究进展,早日为患者带来更多安全、有效、创新的治疗选择。
23rd IMS年会含埃普奈明壁报明细*
*以上含注射用埃普奈明的真实世界/IIT研究入选情况以23rd IMS官方网站更新情况为准,后续更多埃普奈明相关研究于IMS在线收录情况将根据官方网站相关内容的更新而同步公布
Hosted by the International Myeloma Society (IMS), the 23rd IMS Annual Meeting & Exposition will take place from September 23 to 26, 2026, at the Scottish Events Campus (SEC) in Glasgow, UK. Three preclinical and clinical research outcomes of Aponermin for Injection have been accepted for poster presentations at the conference. The research includes exploratory analysis of efficacy biomarkers for Aponermin-based regimens, as well as efficacy and safety evaluations of combination therapies pairing Aponermin with proteasome inhibitors, immunomodulators, XPO-1 inhibitors and BCL-2 inhibitors. These studies focus on patients with relapsed and refractory multiple myeloma (RRMM), a population with substantial treatment challenges such as disease relapse after immunotherapy and prior exposure to multiple agents.
Aponermin for Injection is a circularly permuted endogenous human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). It activates the exogenous apoptosis pathway by binding to death receptor 4 (DR4) and/or death receptor 5 (DR5) on tumor cell membranes, triggering a cascade reaction of intracellular cysteine-aspartic proteases (Caspases) and inducing p53-independent apoptosis. Furthermore, numerous studies have shown that DR4/DR5 agonists exert immunomodulatory effects, which can suppress regulatory T cells, tumor-associated macrophages, myeloid-derived suppressor cells and other immunosuppressive cells in the tumor microenvironment, thereby helping remodel and optimize the tumor immune microenvironment.
As one of the most authoritative annual academic events in the global myeloma field, the IMS Annual Meeting centers on basic research, translational medicine and clinical practice for multiple myeloma and plasma cell disorders. The conference gathers leading experts worldwide to discuss cutting-edge topics including newly diagnosed and relapsed/refractory multiple myeloma, CAR-T therapy, bispecific antibodiestherapy and minimal residual disease (MRD) detection technologies and assessment criteria. Many pivotal clinical trials release their latest data here, making the meeting a core benchmark for advances in myeloma diagnosis and treatment.
In recent years, preclinical studies, real-world case analyses, and interim and early-phase data from investigator-initiated trials (IITs) of Aponermin for Injection have been presented at top-tier global academic conferences including the IMS Annual Meeting. In-depth interpretations covering study design and target mechanisms fully reflect the recognition of DR4/DR5 agonists for hematological malignancies among the international hematology community, as well as the continuously evolving understanding of their pharmacological mechanisms. Wuhan Hiteck Biopharmaceutical Co., Ltd will further accelerate relevant research progress to deliver more safe, effective and innovative treatment options for patients at an early date.
Details of Aponermin-related Posters at the 23rd IMS Annual Meeting*
*The inclusion status of real-world studies and investigator-initiated trials involving Aponermin for Injection is subject to updates on the official website of the 23rd IMS. Additional online publications of Aponermin-related research at IMS will be announced synchronously in accordance with official updates.
23rdIMS年会埃普奈明壁报一览
股票
板块
用户
资讯
评论 (0)